The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Joe Pantginis - H.C. Wainwright & Co., LLC - Analyst
: Hi, Linda and AJ. Good afternoon, thanks for taking the question. So a couple of questions actually.
So first, I wanted to get a little more color or detail -- now, obviously, the answers will be predicated on what the FDA says, but how would you
describe your wish list or goal for what you hope to get out of your upcoming FDA meeting, where you said the primary goal is to present the OLE
data? Are you looking to change the potential launch dynamic, have it potentially come to market earlier? What is the ultimate goal here?
Question: Joe Pantginis - H.C. Wainwright & Co., LLC - Analyst
: And the muscle data certainly speaks for itself in my belief. So I guess I'll ask it in another way as I'm thinking about it. So with regard to the
commercialization dynamic -- so is there a potential, I mean, let's just call it swing for the fences at this point with regard to -- does CAP-1002 have
the potential to be on the market prior to the readout of HOPE-3? And when I say on the market, I mean something like maybe a managed access
Question: Joe Pantginis - H.C. Wainwright & Co., LLC - Analyst
: There you go. Okay. And then, I guess with regard to either concomitant timing of the meeting or a separate meeting with regard to CMC, I'm glad
you're planning ahead with regard to your manufacturing and supplementing out of San Diego lab, I'm glad you made those comments. How
would you potentially project your needs beyond that from a manufacturing standpoint?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 10, 2022 / 8:30PM, CAPR.OQ - Q2 2022 Capricor Therapeutics Inc Earnings Call
Question: Joe Pantginis - H.C. Wainwright & Co., LLC - Analyst
: Got it. And then just lastly, because, obviously, the future has a lot of exosomes being discussed. So you mentioned a couple of things here and in
your press release, too, that you're going to be looking for some preclinical data, maybe get a little more visibility about what kind of things we
might see without necessarily tipping your hand. And you said you also have a potential partnering candidate in the form of a vaccine candidate.
Is that something apart from your COVID candidate that you've discussed previously?
Question: Joe Pantginis - H.C. Wainwright & Co., LLC - Analyst
: Got it. And my last question, if you don't mind -- and it's actually kind of important, I think, just based on the current biotech environment, which
looks like it's starting to bounce back. But cash is king right now, so being able to have a balance into the second quarter of 2024 speaks volumes.
So I wanted to address one of your comments in the press release and AJ's comments about excluding potential strategic uses of this capital. Is
this something that would look to expand your pipeline externally -- from an external source or further expand an exosome program? Or I guess
what kind of things could we look at if that would be one of the options you consider?
Question: Joe Pantginis - H.C. Wainwright & Co., LLC - Analyst
: Got it. Thank you, guys.
|
